Selective Genetics, Inc.

San Diego, CA 92121

SBIR Award Summary

Total Number of Awards 23
Total Value of Awards $5.19MM
First Award Date 07/15/93
Most Recent Award Date 09/10/03

Key Personnel

Last Name Name Awards Contact
Becker Dorothea Becker 1
Sosnowski Barbara A Sosnowski 3
Mc Donald John R Mc Donald 1
Doukas John Doukas 5
Cunningham Mark R Cunningham 1
Chandler Lois A Chandler 1
Larocca David Larocca 7
Phillips Laurie Phillips 1
Faix Peggy H Faix 1
Levy Robert J Levy 1
Gonzalez Ana M Gonzalez 1

23 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/10/03 - 04/01/04

DESCRIPTION (provided by applicant): Adult stem cells from bone marrow have the potential to provide a vast resource for regenerative medicine which would allow the replacement of injured or defective cells and tissues. While it is known that mesenchymal stem cell (MSC) populations from bone marrow have the potential to differentiate into man...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/03 - 08/31/04

DESCRIPTION (provided by applicant): The objective of this proposal is to identify internalizing cardio-specific ligands to target the delivery of therapeutic agents for the treatment of cardiovascular diseases. Gene therapy offers a novel approach for the prevention and treatment of heart disease; however, the fundamental obstacle to improving ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/02 - 08/31/03

The need for effective treatment of chronic dermal wounds is poorly met, despite yearly medical costs exceeding $1 billion. Although growth factors are logical therapeutic candidates, for the most part they have not produced clinically significant benefits. A major limitation has been maintaining therapeutic levels at treatment sites. Delivering...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/02 - 08/31/04

The purpose of this proposal is to develop a platform technology for the identification of targeting ligands for gene therapy. The novel system described here called LIVE (Ligand Identification Via Expression) uses genetic selection to identify phage that display gene targeting ligands. It differs significantly from previous phage display techni...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/29/01 - 08/31/02

The purpose of this proposal is to develop a platform technology for the identification of targeting ligands for gene therapy. The novel system described here called LIVE (Ligand Identification Via Expression) uses genetic selection to identify phage that display gene targeting ligands. It differs significantly from previous phage display techni...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/01 - 09/14/02

Transverse rectus abdominus musculocutaneous (TRAM) flaps are commonly used for tissue reconstruction, especially as required following mastectomy. The success of these flaps is highly dependent on maintaining an adequate blood supply. Despite surgical advances, there remains a relatively high rate of flap necrosis. We propose to improve the sur...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/01 - 08/31/02

The need for effective treatment of chronic dermal wounds is poorly met, despite yearly medical costs exceeding $1 billion. Although growth factors are logical therapeutic candidates, for the most part they have not produced clinically significant benefits. A major limitation has been maintaining therapeutic levels at treatment sites. Delivering...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/31/01 - 12/31/02

Current gene therapy vectors employ animal viruses or condensed DNA/protein complexes to deliver DNA. The use of animal viruses has been limited because of tropism for normal cells, associated toxicity the cost of large-scale production, and the difficulty of genetically altering a complicated virus. Nonverbal systems offer an alternative but ar...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/20/00 - 08/31/01

The need for effective treatment of chronic dermal wounds is poorly met, despite yearly medical costs exceeding $1 billion. Although growth factors are logical therapeutic candidates, for the most part they have not produced clinically significant benefits. A major limitation has been maintaining therapeutic levels at treatment sites. Delivering...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/00 - 02/28/02

Vascular grafts are used in more than 1 million patients each year in the United States (1-3). However, the outcome of vascular graft implantation is often complicated by neointimal buildup at the vascular graft-blood vessel anastomosis. We hypothesize that vascular graft anastomotic obstruction can be prevented through using an antibody-immobil...

Load More